 Home > Active Ingredient News > Urinary System > Research frontiers in this together! The MDT model helps the diagnosis and treatment of metastatic prostate cancer

Research frontiers in this together! The MDT model helps the diagnosis and treatment of metastatic prostate cancer

 Last Update: 2022-10-20
 Source: Internet
 Author: User

Tags

immunotherapy cancer

inductive breast cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Guide

In recent years, the preferred treatment for patients with metastatic prostate cancer (mPC) has shifted from androgen deprivation therapy (ADT) alone to ADT combination
.
Survival rates have been shown to improve in patients receiving ADT plus chemotherapy regimens (ADT + docetaxel), but their use remains challenging
in clinical practice.
The multidisciplinary diagnosis and treatment (MDT) model has been shown to be applicable to a variety of cancer fields and is expected to promote the development of
chemotherapy combined with endocrine therapy in mPC.

Research background

There are often many barriers in the process of translating evidence into clinical practice
.
To explore whether the MDT model can promote the use of ADT plus chemotherapy regimens in mPC patients and to evaluate the impact
of ADT plus chemotherapy regimens on overall survival (OS) in clinical settings.

Study design

All patients diagnosed with mPC (n=962) from the Netherlands Cancer Registry (NCR) were excluded
from October 2015 and April 2016 who did not receive ADT alone or ADT in combination with chemotherapy.
The data extracted from the NCR included information about the general characteristics of the patient, tumor characteristics, and MDT
patterns.
Logistic regression was used to analyze the effect of
MDT mode on treatment decisions (ADT therapy or ADT combined chemotherapy regimen).
The Kaplan-Meier survival curve is used to assess overall survival (OS)
in patients.

Research results

The number of patients in the ADT alone group and the ADT combined chemotherapy group were the same, both with 452 cases
.
Univariate analysis showed that MDT was discussed (OR 4.
47, 95% CI 3.
11 to 6.
42), younger age (odds ratio 0.
85, 95% CI 0.
83 to 0.
87), fewer comorbidities (odds ratio 0.
29, 95% CI 1.
15 to 2.
27), better performance status (OR 0.
24, 95% CI 0.
13 to 0.
45), and higher metastatic burden (OR 1.
39, 95% CI) than ADT alone 1.
07-1.
82) is significantly associated
with the use of ADT in combination with chemotherapy.
After adjusting for confounding variables, MDT discussions were independently associated with the use of ADT plus chemotherapy regimens (OR 2.
77, 95% CI 1.
68 to 4.
59).

Fig.
1 Logistic regression analysis of factors related to treatment decision-making in mPC patients

The 2-year OS was 82.
1% (95% CI 78.
5% to 85.
6%) of patients receiving ADT plus chemotherapy and 59.
9% (95% CI 55.
4% to 64.
4%)
of patients receiving ADT alone.

Fig.
2 OS of patients in both groups of ADT alone and ADT combined with chemotherapy

Conclusion of the study

In this study, the cases discussed with MDT appeared to be more likely to receive ADT in combination with chemotherapy
.
The MDT model is conducive to promoting the practical application
of innovative treatment decisions in the clinic.

References:

Creemers SG, Van Santvoort B, van den Berkmortel FWPJ, et al.
Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice.
Prostate Cancer Prostatic Dis.
2022 Jul 7.
doi: 10.
1038/s41391-022-00556-z.

Editor: Mumu Wang

Review: LR

Execution: Wang Mumu

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.